Back to library
GH SecretagogueSubcutaneous
ACE-031
Also known as: Activin Receptor Type IIB-Fc · ActRIIB-Fc
Recombinant fusion protein combining the extracellular domain of activin receptor IIB with an IgG Fc fragment. Acts as a decoy receptor for myostatin, activin A, and related TGF-β superfamily ligands — preventing their muscle-restraining signaling.
At a glance
- Half-life
- 10 days
- Common route
- Subcutaneous
- Typical dose range
- 1,000–3,000mcg
- Stability (reconstituted)
- 30days refrigerated
Best timing
Once weekly to once every two weeks due to long half-life from Fc fragment. Trial development halted at Phase 2 — limited current human data.
Contraindications
- Pregnancy
- Active cancer
- Cardiovascular disease (vascular adverse events were the reason for halted development)
- Bleeding tendency or epistaxis history
Watch symptoms
- Nosebleeds and gum bleeding (the primary trial-halting adverse events)
- Telangiectasias (small visible blood vessels)
- Injection site reactions
- Headache
- Theoretical cardiac and bone effects from broad TGF-β family blockade